Boston's shares slip further 10% in heavy trading:
This article was originally published in Clinica
Boston Scientific's fall from grace continues. Last Wednesday saw a further 10% or $2.25 fall in its share price to $21. Analysts could not explain the fall, on a volume three times that of a normal day's trading, but suggested that it may be a reaction to the rumoured slowdown in the hitherto rapid growth of the US stent market.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.